| 摘要 |
<p>The present invention relates to a new therapeutic approach to treating apolipoprotein CIII (apoCIII)-induced hypertriglyceridemia when linked to over-expression of apoCIII that relies on increasing availability of the lipid transporter ABCA1, or a functional variant thereof, to promote accumulation of apoCIII on HDL (high density lipoprotein) and thereby reduce accumulation of apoCIII on VLDL (very low density lipoprotein) and the subsequent inhibition of lipoprotein lipase. This therapeutic approach can be extended to other apolipoprotein-induced hypertriglyceridemia as well as other disease aspects of metabolic syndrome linked to accumulation of triglyceride-rich VLDL with abnormal apolipoprotein composition.</p> |
